All in the family: Clueing into the link between metabolic syndrome and hematologic malignancies

Reem Karmali*, Andrew Dalovisio, Jeffrey A. Borgia, Parameswaran Venugopal, Brian W. Kim, Kelly Grant Szymanski, Parameswaran Hari, Hillard Lazarus

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


Metabolic syndrome constitutes a constellation of findings including central obesity, insulin resistance/type 2 diabetes mellitus (DM), dyslipidemia and hypertension. Metabolic syndrome affects 1 in 4 adults in the United States and is rapidly rising in prevalence, largely driven by the dramatic rise in obesity and insulin resistance/DM. Being central to the development of metabolic syndrome and its other related diseases, much focus has been placed on identifying the mitogenic effects of obesity and insulin resistance/DM as mechanistic clues of the link between metabolic syndrome and cancer. Pertinent mechanisms identified include altered lipid signaling, adipokine and inflammatory cytokine effects, and activation of PI3K/Akt/mTOR and RAS/RAF/MAPK/ERK pathways via dysregulated insulin/insulin-like growth factor-1 (IGF-1) signaling. Through variable activation of these multiple pathways, obesity and insulin resistance/DM pre-dispose to hematologic malignancies, imposing the aggressive and chemo-resistant phenotypes typically seen in cancer patients with underlying metabolic syndrome. Growing understanding of these pathways has identified druggable cancer targets, rationalizing the development and testing of agents like PI3K inhibitor idelalisib, mTOR inhibitors everolimus and temsirolimus, and IGF-1 receptor inhibitor linsitinib. It has also led to exploration of obesity and diabetes-directed therapies including statins and oral hypoglycemic for the management of metabolic syndrome-related hematologic neoplasms.

Original languageEnglish (US)
Pages (from-to)71-80
Number of pages10
JournalBlood Reviews
Issue number2
StatePublished - 2015


  • Adipokines
  • Dyslipidemia
  • Hematologic malignancy
  • IGF-1
  • Inflammation
  • Insulin resistance
  • Insulin signaling
  • Lipid signaling
  • Metabolic syndrome
  • Metformin
  • Obesity
  • Reactive oxygen species

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'All in the family: Clueing into the link between metabolic syndrome and hematologic malignancies'. Together they form a unique fingerprint.

Cite this